Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:53 UTC |
---|
HMDB ID | HMDB0015164 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Topotecan |
---|
Description | Topotecan is only found in individuals that have used or taken this drug. It is an antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. [PubChem]Topotecan has the same mechanism of action as irinotecan and is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death).Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor. |
---|
Structure | CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1 |
---|
Synonyms | Value | Source |
---|
9-[(Dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin | ChEBI | Topotecane | ChEBI | Topotecanum | ChEBI | Hycamtin | Kegg | Topotecan lactone | HMDB | SK And F 104864 a | HMDB | SK And F-104864-a | HMDB | SK And F104864a | HMDB | Topotecan hydrochloride | HMDB | 9-Dimethylaminomethyl-10-hydroxycamptothecin | HMDB | Nogitecan hydrochloride | HMDB | SmithKline beecham brand OF topotecan hydrochloride | HMDB | Hycamtamine | HMDB | Hydrochloride, nogitecan | HMDB | Topotecan monohydrochloride, (S)-isomer | HMDB | 9 Dimethylaminomethyl 10 hydroxycamptothecin | HMDB | Hydrochloride, topotecan | HMDB |
|
---|
Chemical Formula | C23H23N3O5 |
---|
Average Molecular Weight | 421.4458 |
---|
Monoisotopic Molecular Weight | 421.163770861 |
---|
IUPAC Name | (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione |
---|
Traditional Name | topotecan |
---|
CAS Registry Number | 119413-54-6 |
---|
SMILES | CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O |
---|
InChI Identifier | InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1 |
---|
InChI Key | UCFGDBYHRUNTLO-QHCPKHFHSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring). |
---|
Kingdom | Organic compounds |
---|
Super Class | Alkaloids and derivatives |
---|
Class | Camptothecins |
---|
Sub Class | Not Available |
---|
Direct Parent | Camptothecins |
---|
Alternative Parents | |
---|
Substituents | - Camptothecin
- Hydroxyquinoline
- Pyranopyridine
- Quinoline
- 1-hydroxy-2-unsubstituted benzenoid
- Pyridinone
- Aralkylamine
- Benzenoid
- Pyridine
- Heteroaromatic compound
- Tertiary alcohol
- Carboxylic acid ester
- Amino acid or derivatives
- Lactam
- Tertiary aliphatic amine
- Tertiary amine
- Lactone
- Oxacycle
- Carboxylic acid derivative
- Azacycle
- Organoheterocyclic compound
- Monocarboxylic acid or derivatives
- Organopnictogen compound
- Alcohol
- Organic oxide
- Hydrocarbon derivative
- Carbonyl group
- Organic nitrogen compound
- Organonitrogen compound
- Organooxygen compound
- Organic oxygen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 213 - 218 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.86 g/L | Not Available | LogP | 0.8 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Topotecan,1TMS,isomer #1 | CC[C@@]1(O[Si](C)(C)C)C(=O)OCC2=C1C=C1C3=NC4=CC=C(O)C(CN(C)C)=C4C=C3CN1C2=O | 3617.4 | Semi standard non polar | 33892256 | Topotecan,1TMS,isomer #2 | CC[C@@]1(O)C(=O)OCC2=C1C=C1C3=NC4=CC=C(O[Si](C)(C)C)C(CN(C)C)=C4C=C3CN1C2=O | 3622.2 | Semi standard non polar | 33892256 | Topotecan,2TMS,isomer #1 | CC[C@@]1(O[Si](C)(C)C)C(=O)OCC2=C1C=C1C3=NC4=CC=C(O[Si](C)(C)C)C(CN(C)C)=C4C=C3CN1C2=O | 3605.3 | Semi standard non polar | 33892256 | Topotecan,1TBDMS,isomer #1 | CC[C@@]1(O[Si](C)(C)C(C)(C)C)C(=O)OCC2=C1C=C1C3=NC4=CC=C(O)C(CN(C)C)=C4C=C3CN1C2=O | 3810.2 | Semi standard non polar | 33892256 | Topotecan,1TBDMS,isomer #2 | CC[C@@]1(O)C(=O)OCC2=C1C=C1C3=NC4=CC=C(O[Si](C)(C)C(C)(C)C)C(CN(C)C)=C4C=C3CN1C2=O | 3831.6 | Semi standard non polar | 33892256 | Topotecan,2TBDMS,isomer #1 | CC[C@@]1(O[Si](C)(C)C(C)(C)C)C(=O)OCC2=C1C=C1C3=NC4=CC=C(O[Si](C)(C)C(C)(C)C)C(CN(C)C)=C4C=C3CN1C2=O | 3972.3 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Topotecan GC-MS (Non-derivatized) - 70eV, Positive | splash10-01rw-0019000000-dd5f6ac57d5951105684 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Topotecan GC-MS (2 TMS) - 70eV, Positive | splash10-0kmi-3001490000-ae90c2325c77269d874b | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Topotecan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Topotecan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Topotecan , positive-QTOF | splash10-00b9-0019400000-11f24a2a9b88f6c67514 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topotecan 35V, Positive-QTOF | splash10-004i-1009000000-b9244ee1f6cd61fee4f2 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topotecan 35V, Negative-QTOF | splash10-004i-0009000000-d66ee57d6e010d309c66 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 10V, Positive-QTOF | splash10-00di-0006900000-89514722d3cccd3d4496 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 20V, Positive-QTOF | splash10-00b9-0019300000-58bcf8842222fe631eca | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 40V, Positive-QTOF | splash10-004i-1097000000-5b71ebf26d18a059bf0c | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 10V, Negative-QTOF | splash10-00di-0004900000-c6c85b983396e6199196 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 20V, Negative-QTOF | splash10-00fr-1009500000-740f8b3ec7e0bca5f75f | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 40V, Negative-QTOF | splash10-0pwc-3029000000-65747933e72b20c9b71f | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 10V, Positive-QTOF | splash10-00b9-0009500000-6c4802693f32d6eec744 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 20V, Positive-QTOF | splash10-004i-0009000000-258882d388fa7db50bff | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 40V, Positive-QTOF | splash10-05i3-4039100000-203d71abf98396934b86 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 10V, Negative-QTOF | splash10-004i-0009100000-c19a7f2e40a8ab89986a | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 20V, Negative-QTOF | splash10-004i-0009000000-a6970c65760ce14af472 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topotecan 40V, Negative-QTOF | splash10-01di-1029000000-30fc22abe375909eff46 | 2021-10-11 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum |
|
---|